Bicara Therapeutics (BCAX) Return on Capital Employed (2024 - 2026)

Bicara Therapeutics posted quarterly Return on Capital Employed of 38.43% for Q1 2026, down 1552.0% year-on-year from 2.65% in Q1 2025, and up 1.49% on a QoQ basis from 39.01% in Q4 2025.

Bicara Therapeutics (BCAX) has 3 years of Return on Capital Employed data on file, last reported at 38.43% in Q1 2026.

  • For the quarter ending Q1 2026, Return on Capital Employed fell 1552.0% year-over-year to 38.43%; the trailing twelve-month figure through Mar 2026 stood at 38.43% (down 1552.0% YoY), and the FY2025 full-year result was 35.24%, down 1197.0% from the prior year.
  • Return on Capital Employed for Q1 2026 stood at 38.43%, up from 39.01% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 16.51% in Q4 2024 and bottomed at 39.01% in Q4 2025.
  • The 3-year median for Return on Capital Employed is 30.37% (2025), against an average of 29.6%.
  • The widest annual swing landed in 2025, when Return on Capital Employed sank 2250 bps; it then plunged 1552 bps in 2026.
  • A 3-year view of Return on Capital Employed shows it stood at 16.51% in 2024, then plunged by 136 bps to 39.01% in 2025, then rose by 1 bps to 38.43% in 2026.
  • The last three Return on Capital Employed figures came in at 38.43% (Q1 2026), 39.01% (Q4 2025), and 33.75% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 450.31%
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 51.73%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -107.40%
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 21.10%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 10.19%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 20.34%
10 Bicara Therapeutics 1.25 Bn 1.25 Bn - -38.43%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -38.43%
Dec 31, 2025 -39.01%
Sep 30, 2025 -33.75%
Jun 30, 2025 -26.99%
Mar 31, 2025 -22.91%
Dec 31, 2024 -16.51%